Market: NASD |
Currency: USD
Address: 320 West 37th Street
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
📈 Immunovant, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$40.21
-
Upside/Downside from Analyst Target:
173.75%
-
Broker Call:
24
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-06
-
EPS Estimate:
-0.72
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Immunovant, Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-11 | -0.71 |
| 2025-05-29 | -0.64 |
| 2025-02-06 | -0.76 |
| 2024-11-07 | -0.74 |
| 2024-08-06 | -0.6 |
| 2024-05-29 | -0.52 |
| 2024-02-12 | -0.36 |
| 2023-11-09 | -0.45 |
| 2023-08-10 | -0.57 |
| 2023-05-22 | -0.46 |
| 2023-02-03 | -0.49 |
| 2022-11-04 | -0.41 |
| 2022-08-05 | -0.35 |
| 2022-06-08 | -0.41 |
| 2022-02-04 | -0.36 |
| 2021-11-05 | -0.35 |
| 2021-08-09 | -0.31 |
| 2021-06-01 | -0.29 |
| 2021-02-16 | -0.32 |
| 2020-11-12 | -0.25 |
| 2020-08-12 | -0.38 |
| 2020-06-29 | -0.38 |
| 2020-02-14 | -0.28 |
📰 Related News & Research
No related articles found for "immunovant inc".
